Search Results

Humhealth, a leading provider of innovative remote care solutions, has the capability to integrate with an advanced 4G Telehealth Gateway Hub and 4G vital monitoring devices.

G1 Therapeutics, Inc. today announced the grant of inducement stock options exercisable for 4,650 shares of G1’s common stock and 2,400 restricted stock units (RSUs) to one hired employee under the Amended and Restated G1 Therapeutics, Inc. 2021 Inducement Equity Incentive Plan (the “Amended and Restated 2021 Plan”).

Gel4Med, an innovative biomaterials company, is proud to announce that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its first biosynthetic matrix products, G4Derm and G4Derm Plus.

Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, today unveiled the G4X™ Spatial Sequencer.

MedMira Inc. proudly announces the successful attainment of 510 clearance for the HIV-2 claim on the Reveal® G4 Rapid HIV-1/2 antibody test in the United States.

G1 Therapeutics, Inc., a commercial-stage oncology company, announced the grant of inducement stock options exercisable for 4,700 shares of G1’s common stock and 2,300 restricted stock units to one hired employee under the Amended and Restated G1 Therapeutics, Inc. 2021 Inducement Equity Incentive Plan.

Singular Genomics Systems, Inc. announced groundbreaking new products and capabilities at the Advances of Genome Biology and Technology conference in Orlando, Florida.

Affini-T Therapeutics, Inc today announced that the first patient has been dosed in the Company’s Phase 1 clinical trial evaluating AFNT-211 targeting KRAS G12V. A Trial-In-Progress poster for this ongoing Phase 1 trial will be presented at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting held in Chicago, IL May 31-June 4.